The transition from relapsing-remitting MS to irreversible disability: clinical evaluation

被引:0
|
作者
M. Trojano
D. Paolicelli
A. Bellacosa
S. Cataldo
机构
[1] University of Bari,Department of Neurological and Psychiatric Sciences
来源
Neurological Sciences | 2003年 / 24卷
关键词
Multiple sclerosis; Disease duration; Prognosis; Age; Disability progression;
D O I
暂无
中图分类号
学科分类号
摘要
The development of a progressive course is by far the most deleterious event in the case of a multiple sclerosis (MS) patient. It occurs in about 90% of relapsing remitting patients by 20–25 years from onset. The clinical transition to secondary progressive MS is phenotypically distinctive and both patients and physicians acknowledge that a fundamental shift in the degree of responsiveness to anti-inflammatory therapies has occurred. This review discusses the clinical studies that provided important findings relating to our understanding on different mechanisms that may contribute to irreversible disability in MS.
引用
收藏
页码:s268 / s270
相关论文
共 50 条
  • [1] The transition from relapsing-remitting MS to irreversible disability: clinical evaluation
    Trojano, M
    Paolicelli, D
    Bellacosa, A
    Cataldo, S
    NEUROLOGICAL SCIENCES, 2003, 24 (Suppl 5) : S268 - S270
  • [2] Measuring disability in relapsing-remitting MS
    Rudick, Richard A.
    Kappos, Ludwig
    NEUROLOGY, 2010, 75 (04) : 296 - 297
  • [3] From relapsing-remitting to secondary progressive MS
    Fox, R.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 63 - 63
  • [4] Clinical characteristics of Hispanic patients with relapsing-remitting MS
    Derwenskus, J
    Tullman, MJ
    Lublin, FD
    MULTIPLE SCLEROSIS, 2005, 11 (01): : 115 - 116
  • [5] Predicting the course of relapsing-remitting MS using longitudinal disability curves
    Anat Achiron
    Journal of Neurology, 2004, 251 : v65 - v68
  • [6] Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
    Giovannoni, Gavin
    Cohen, Jeffrey A.
    Coles, Alasdair J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Margolin, David H.
    Lake, Stephen L.
    Kaup, Susan M.
    Panzara, Michael A.
    Compston, D. Alastair S.
    NEUROLOGY, 2016, 87 (19) : 1985 - 1992
  • [7] Predicting the course of relapsing-remitting MS using longitudinal disability curves
    Achiron, A
    JOURNAL OF NEUROLOGY, 2004, 251 (Suppl 5) : 65 - 68
  • [8] Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis
    Rudick, Richard A.
    Lee, Jar-Chi
    Cutter, Gary R.
    Miller, Deborah M.
    Bourdette, Dennis
    Weinstock-Guttman, Bianca
    Hyde, Robert
    Zhang, Hao
    You, Xiaojun
    ARCHIVES OF NEUROLOGY, 2010, 67 (11) : 1329 - 1335
  • [9] The clinical impact of interferon beta antibodies in relapsing-remitting MS
    Paola Perini
    Massimiliano Calabrese
    Giovanni Biasi
    Paolo Gallo
    Journal of Neurology, 2004, 251 : 305 - 309
  • [10] Is relapsing-remitting MS a benign disease?
    Rolak, L. A.
    Anderson, S.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 232 - 233